NCT03396445 - Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) | Biotech Hunter

Enrollment

182

Participants

Timeline

Start Date

February 18, 2018

Primary Completion Date

September 27, 2024

Study Completion Date

September 27, 2024

Conditions

PharmacokineticsSolid TumorCarcinoma, Non-Small-Cell LungTriple Negative Breast Neoplasms

Interventions

DRUG

Boserolimab

IV infusion

BIOLOGICAL

Pembrolizumab

IV infusion

DRUG

Pemetrexed

IV infusion

DRUG

Carboplatin

IV infusion

DRUG

Nab-paclitaxel

IV infusion

Trial Locations (18)

100

National Taiwan University Hospital-Oncology ( Site 0801), Taipei

112

Koo Foundation Sun Yat-Sen Cancer Center ( Site 0802), Taipei

28040

Hospital Universitario Fundacion Jimenez Diaz ( Site 0041), Madrid

28050

Centro Integral Oncologico Clara Campal START Madrid ( Site 0040), Madrid

28223

Hospital Universitario Quiron Madrid ( Site 0043), Pozuelo de Alarcón

34232

Florida Cancer Specialists ( Site 0002), Sarasota

36604

University of South Alabama, Mitchell Cancer Institute ( Site 0020), Mobile

38138

The West Clinic, P.C. ( Site 0021), Germantown

5265601

The Chaim Sheba Medical Center - Oncology Institute ( Site 0001), Ramat Gan

6900941

FALP-UIDO ( Site 0502), Santiago

8400000

Soroka Medical Center-Oncology ( Site 0012), Beersheba

8420383

Bradfordhill-Clinical Area ( Site 0501), Santiago

9112001

Hadassah Ein Kerem Medical Center ( Site 0010), Jerusalem

1066 CX

Antoni van Leeuwenhoek Ziekenhuis ( Site 0003), Amsterdam

3015 GD

Erasmus MC ( Site 0031), Rotterdam

03080

Seoul National University Hospital-Internal Medicine ( Site 0702), Seoul

03722

Severance Hospital, Yonsei University Health System-Medical oncology ( Site 0701), Seoul

08916

Instituto Catalan de Oncologia - ICO ( Site 0044), Barcelona

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY